FDA Statement on risk of cardiovascular events in patients receiving Celebrex

[Brian, ASN, RN]

MedWatch - The FDA Safety Information and Adverse Event Reporting Program

FDA notified healthcare professionals that, based on emerging information,

including preliminary reports from one of several long term National

Institutes of Health (NIH) prevention studies, the risk of cardiovascular

events may be increased in patients receiving Celebrex. FDA is analyzing all

available information from these studies to determine whether additional

regulatory action is needed.

Read the MedWatch 2004 safety summary, including a link to the FDA Statement

and Drug Information Page at:

http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Celebrex